Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy

BACKGROUND: Although immune checkpoint blockade is effective for several malignancies, a substantial number of patients remain refractory to treatment. The future of immunotherapy will be a personalized approach adapted to each patient’s cancer-immune interactions in the tumor microenvironment (TME)...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagaoka, Koji, Shirai, Masataka, Taniguchi, Kiyomi, Hosoi, Akihiro, Sun, Changbo, Kobayashi, Yukari, Maejima, Kazuhiro, Fujita, Masashi, Nakagawa, Hidewaki, Nomura, Sachiyo, Kakimi, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583806/
https://www.ncbi.nlm.nih.gov/pubmed/33093158
http://dx.doi.org/10.1136/jitc-2020-001358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583806/
https://www.ncbi.nlm.nih.gov/pubmed/33093158
http://dx.doi.org/10.1136/jitc-2020-001358

Ejemplares similares